Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer

Table 1 Transcripts differentially regulated in HepG2 cells in response to erlotinib

GenBankID	Gene name	Mean1	SD
M62402	Insulin-like growth factor binding protein 6	5.85	0.73
S66431	Retinoblastoma-binding protein 2	3.22	0.39
U13737	Caspase 3. apoptosis-related cysteine protease	3.18	0.52
Y09392	Tumor necrosis factor receptor superfamily. member 12 (translocating chain-association membrane protein)	3.04	0.61
M60974	Gadd45	2.37	0.34
S40706	Gadd153	2.31	0.09
M25753	Cyclin B1	2.21	0.47
U37448	Caspase 7. apoptosis-related cysteine protease	2.10	0.34
L16785	Non-metastatic cells 2. protein (NM23B)	2.03	0.22
U23765	BCL2-antagonist/killer 1	0.53	0.13
X51688	Cyclin A2	0.50	0.32
M34065	Cell division cycle 25C	0.49	0.06
L22005	Cell division cycle 34	0.48	0.17
X85134	Retinoblastoma-binding protein 5	0.38	0.12
L25676	Cyclin-dependent kinase 9 (CDC2-related kinase)	0.38	0.05
U66879	BCL2-antagonist of cell death	0.36	0.05
D25216	KIAA0014 gene product	0.35	0.14
X86779	Fas-activated serine/threonine kinase	0.30	0.06
L29220	CDC-like kinase 3	0.28	0.03
X74262	Retinoblastoma-binding protein 4	0.27	0.09
M14505	Cyclin-dependent kinase 4	0.25	0.07
AF010312	LPS-induced TNF-alpha factor	0.24	0.06
U25265	Mitogen-activated protein kinase 5	0.22	0.03
M15796	Proliferating cell nuclear antigen	0.17	0.03
X56681	Jun D proto-oncogene	0.13	0.06

¹ Arithmetic means of ratios (treated:untreated) from three separate array measurements.